A retrospective study published in the International Journal of Womens Dermatology suggested that spironolactone may benefit women of childbearing age with mild hidradenitis suppurativa (HS), particularly if started early.

The study was conducted at a single center and included 157 women aged 12-50 years who were treated with spironolactone for at least three months between 2000 and 2021 at Michigan Medicine outpatient dermatology clinics. The demographic breakdown of the patients was predominantly White (59%) and Black (37%). The median dose prescribed was 100 mg/day, with the most common dosage ranging from 50-100 mg/day.

The findings revealed that only 20% of the patients showed improvement with spironolactone treatment. Additionally, a shorter time between HS diagnosis and the initiation of spironolactone was linked to better outcomes. Hurley stage III HS patients were 85% less likely to benefit from spironolactone.

 The authors concluded that spironolactone may be effective for patients with mild HS, particularly those at Hurley stage I, when used early as a primary or supplementary treatment due to its antiandrogenic properties.

(Source:https://www.medscape.com/viewarticle/spironolactone-may-benefit-women-hidradenitis-suppurativa-2024a1000cpk)